NEW YORK & LEAMINGTON, Ontario--(BUSINESS WIRE)--Tilray, Inc. (“Tilray”) (NASDAQ | TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company, today announced the launch of Symbios, a complement to the Company’s existing medical brand portfolio in Canada. This new brand was developed to provide a broader spectrum of formats and unique cannabinoid ratios at a better price point while offering medical patients a full comprehensive assortment of products, including flower, oils, and pre-rolls for their health and wellness regiment.
Irwin D. Simon, Tilray’s Chief Executive Officer, said, “Medical cannabis innovation and patient care are core to the new Tilray’s business and global growth strategy. As we look ahead, we remain focused on building momentum across our three medical brands – Symbios, Aphria, and Tilray -- while meeting the large and growing demand for new, high-quality cannabis products that promote health, wellness, and wellbeing.”
Contemporaneous with today’s announcement, Tilray also announced new high-potency, medical cannabis topicals under the Aphria brand designed to target inflammatory joint disease by regulating tissue inflammation when applied topically to the skin1. They are made from a vegan and cruelty-free cream formulation and include CBD 750 (containing 750mg of CBD) and Balance 750 (containing 375mg of THC and 375mg of CBD).
Jim Meiers, President, Tilray Canada, added, “Symbios and our new Aphria topical treatments are exciting new additions to our medical portfolio in Canada, providing our patients with a broader selection of unique product formats to meet their needs and preferences. Our industry is only in the early stages of creating and bringing to market cannabinoid medicine options that meet patient needs. We are committed to building our leadership position in Canada now and into the future.”
Symbios and Aphria’s new high-potency topicals join a range of other products, including cannabis oils, soft gels, oral sprays, whole dried flower, and vapes that are now available to all medical patients through the Aphria online medical patient portal.
For more information about Symbios and Aphria medical cannabis products, visit: www.Aphria.ca
About Aphria, Tilray’s Medical Cannabis Brand
Aphria started in 2014 in Leamington, Ontario, as one of the first companies to provide access to legal, medical cannabis. Since then, the Aphria brand has grown to be one of the top medical cannabis providers globally, with operations in Canada and international markets. Aphria remains committed to supplying its growing patient base with safe, affordable, consistent, and effective medical cannabis products.
Tilray, Inc. is a leading global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is changing people’s lives for the better – one person at a time – by inspiring and empowering the worldwide community to live their very best life by providing them with products that meet the needs of their mind, body, and soul and invoke a sense of wellbeing. Tilray’s mission is to be the trusted partner for its patients and consumers by providing them with a cultivated experience and health and wellbeing through high-quality, differentiated brands and innovative products. A pioneer in cannabis research, cultivation, and distribution, Tilray’s unprecedented production platform supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and alcoholic beverages.
For more information about Tilray, Inc., visit: www.Tilray.com
Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Many factors could cause actual results, performance or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Aphria and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with applicable securities regulatory authorities and available on SEDAR and EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.
1 Philpott, Holly T., et al. “Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis.” Pain. 2017 Dec; 158(12). DOI: 10.1097/j.pain.0000000000001052